Voyager Therapeutics宣布首次发表同行评审的数据，显示碱性磷酸酶能够将新型AAC病毒病毒包裹穿过血脑屏障

Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled "Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier," was published in Molecular Therapy and can be accessed here.